Elevation Net Working Capital vs Total Assets Analysis

ELEV Stock

USD 0.67 0.01 1.52%

Elevation Oncology financial indicator trend analysis is much more than just examining Elevation Oncology latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Elevation Oncology is a good investment. Please check the relationship between Elevation Oncology Net Working Capital and its Total Assets accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.

Net Working Capital vs Total Assets

Net Working Capital vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Elevation Oncology Net Working Capital account and Total Assets. At this time, the significance of the direction appears to have totally related.

The correlation between Elevation Oncology's Net Working Capital and Total Assets is 1.0. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Total Assets in the same time period over historical financial statements of Elevation Oncology, assuming nothing else is changed. The correlation between historical values of Elevation Oncology's Net Working Capital and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Elevation Oncology are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Working Capital i.e., Elevation Oncology's Net Working Capital and Total Assets go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Working Capital

Total Assets

Total assets refers to the total amount of Elevation Oncology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Elevation Oncology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most indicators from Elevation Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Elevation Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.At this time, Elevation Oncology's Tax Provision is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 56.1 M in 2025, whereas Selling General Administrative is likely to drop slightly above 9.2 M in 2025.

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	27K	39K	44.9K	27.2K
Cost Of Revenue	27K	39K	44.9K	27.2K

Reconciled Depreciation Cost Of Revenue

Elevation Oncology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Other Liab	Non Currrent Assets Other	Other Assets	Non Current Liabilities Other	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total
Total Assets		0.75	0.82	0.86	0.85	-0.77	-0.75	0.67	0.95	1.0	0.46	0.42	0.94	0.63	0.52	0.89	1.0	1.0	-0.81	0.61	0.21	-0.81	0.2	0.5	0.62	0.47
Other Current Liab	0.75		0.92	0.64	0.63	-0.28	-0.82	0.6	0.54	0.75	0.36	0.27	0.67	0.75	0.4	0.75	0.75	0.72	-0.87	0.83	0.73	-0.87	0.76	0.4	0.82	0.38
Total Current Liabilities	0.82	0.92		0.63	0.63	-0.53	-0.66	0.82	0.72	0.82	0.13	0.43	0.64	0.55	0.56	0.68	0.82	0.79	-0.74	0.6	0.69	-0.74	0.61	0.18	0.59	0.23
Total Stockholder Equity	0.86	0.64	0.63		1.0	-0.69	-0.63	0.45	0.83	0.86	0.39	-0.1	0.92	0.61	0.02	0.98	0.86	0.87	-0.74	0.49	0.13	-0.74	0.02	0.43	0.51	0.38
Net Tangible Assets	0.85	0.63	0.63	1.0		-0.71	-0.6	0.47	0.83	0.85	0.35	-0.11	0.9	0.58	0.0	0.97	0.85	0.86	-0.71	0.46	0.14	-0.71	0.01	0.39	0.47	0.35
Net Debt	-0.77	-0.28	-0.53	-0.69	-0.71		0.17	-0.73	-0.92	-0.78	0.01	-0.32	-0.65	-0.02	-0.39	-0.59	-0.77	-0.78	0.26	0.02	0.05	0.26	0.33	-0.01	0.0	-0.02
Retained Earnings	-0.75	-0.82	-0.66	-0.63	-0.6	0.17		-0.2	-0.52	-0.74	-0.77	-0.29	-0.8	-0.96	-0.37	-0.77	-0.75	-0.74	0.98	-0.94	-0.26	0.98	-0.56	-0.81	-0.95	-0.69
Accounts Payable	0.67	0.6	0.82	0.45	0.47	-0.73	-0.2		0.7	0.68	-0.22	0.52	0.42	0.01	0.62	0.42	0.67	0.64	-0.28	0.16	0.59	-0.28	0.26	-0.2	0.15	-0.18
Cash	0.95	0.54	0.72	0.83	0.83	-0.92	-0.52	0.7		0.95	0.26	0.39	0.85	0.39	0.48	0.78	0.95	0.95	-0.59	0.32	0.05	-0.59	-0.06	0.29	0.34	0.31
Cash And Short Term Investments	1.0	0.75	0.82	0.86	0.85	-0.78	-0.74	0.68	0.95		0.44	0.42	0.93	0.61	0.52	0.88	1.0	1.0	-0.79	0.59	0.21	-0.79	0.19	0.48	0.6	0.45
Common Stock Shares Outstanding	0.46	0.36	0.13	0.39	0.35	0.01	-0.77	-0.22	0.26	0.44		0.2	0.66	0.77	0.19	0.53	0.46	0.48	-0.69	0.79	-0.22	-0.69	0.2	1.0	0.81	0.84
Non Current Liabilities Total	0.42	0.27	0.43	-0.1	-0.11	-0.32	-0.29	0.52	0.39	0.42	0.2		0.2	0.07	0.99	-0.01	0.42	0.41	-0.21	0.27	0.12	-0.21	0.25	0.2	0.26	0.17
Other Current Assets	0.94	0.67	0.64	0.92	0.9	-0.65	-0.8	0.42	0.85	0.93	0.66	0.2		0.73	0.29	0.96	0.94	0.95	-0.85	0.68	0.04	-0.85	0.1	0.69	0.7	0.58
Other Stockholder Equity	0.63	0.75	0.55	0.61	0.58	-0.02	-0.96	0.01	0.39	0.61	0.77	0.07	0.73		0.14	0.74	0.63	0.62	-0.96	0.91	0.21	-0.96	0.55	0.8	0.92	0.77
Total Liab	0.52	0.4	0.56	0.02	0.0	-0.39	-0.37	0.62	0.48	0.52	0.19	0.99	0.29	0.14		0.1	0.52	0.5	-0.31	0.34	0.23	-0.31	0.33	0.21	0.33	0.17
Net Invested Capital	0.89	0.75	0.68	0.98	0.97	-0.59	-0.77	0.42	0.78	0.88	0.53	-0.01	0.96	0.74	0.1		0.88	0.89	-0.85	0.67	0.21	-0.85	0.19	0.57	0.68	0.49
Total Current Assets	1.0	0.75	0.82	0.86	0.85	-0.77	-0.75	0.67	0.95	1.0	0.46	0.42	0.94	0.63	0.52	0.88		1.0	-0.8	0.6	0.2	-0.8	0.2	0.5	0.62	0.46
Net Working Capital	1.0	0.72	0.79	0.87	0.86	-0.78	-0.74	0.64	0.95	1.0	0.48	0.41	0.95	0.62	0.5	0.89	1.0		-0.79	0.59	0.16	-0.79	0.15	0.52	0.61	0.48
Other Liab	-0.81	-0.87	-0.74	-0.74	-0.71	0.26	0.98	-0.28	-0.59	-0.79	-0.69	-0.21	-0.85	-0.96	-0.31	-0.85	-0.8	-0.79		-0.91	-0.33	1.0	-0.55	-0.74	-0.92	-0.67
Non Currrent Assets Other	0.61	0.83	0.6	0.49	0.46	0.02	-0.94	0.16	0.32	0.59	0.79	0.27	0.68	0.91	0.34	0.67	0.6	0.59	-0.91		0.4	-0.91	0.69	0.81	1.0	0.66
Other Assets	0.21	0.73	0.69	0.13	0.14	0.05	-0.26	0.59	0.05	0.21	-0.22	0.12	0.04	0.21	0.23	0.21	0.2	0.16	-0.33	0.4		-0.33	0.82	-0.2	0.37	-0.18
Non Current Liabilities Other	-0.81	-0.87	-0.74	-0.74	-0.71	0.26	0.98	-0.28	-0.59	-0.79	-0.69	-0.21	-0.85	-0.96	-0.31	-0.85	-0.8	-0.79	1.0	-0.91	-0.33		-0.55	-0.74	-0.92	-0.67
Intangible Assets	0.2	0.76	0.61	0.02	0.01	0.33	-0.56	0.26	-0.06	0.19	0.2	0.25	0.1	0.55	0.33	0.19	0.2	0.15	-0.55	0.69	0.82	-0.55		0.21	0.67	0.28
Common Stock	0.5	0.4	0.18	0.43	0.39	-0.01	-0.81	-0.2	0.29	0.48	1.0	0.2	0.69	0.8	0.21	0.57	0.5	0.52	-0.74	0.81	-0.2	-0.74	0.21		0.83	0.83
Property Plant Equipment	0.62	0.82	0.59	0.51	0.47	0.0	-0.95	0.15	0.34	0.6	0.81	0.26	0.7	0.92	0.33	0.68	0.62	0.61	-0.92	1.0	0.37	-0.92	0.67	0.83		0.7
Short Long Term Debt Total	0.47	0.38	0.23	0.38	0.35	-0.02	-0.69	-0.18	0.31	0.45	0.84	0.17	0.58	0.77	0.17	0.49	0.46	0.48	-0.67	0.66	-0.18	-0.67	0.28	0.83	0.7

Click cells to compare fundamentals

Elevation Oncology Account Relationship Matchups

Elevation Oncology fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	80.9M	149.5M	94.2M	89.1M	102.5M	91.4M
Other Current Liab	1.1M	3.1M	9.3M	3.6M	4.2M	3.8M
Total Current Liabilities	6.8M	8.8M	15.7M	4.1M	4.8M	7.9M
Total Stockholder Equity	(23.1M)	140.7M	49.0M	54.8M	63.0M	47.4M
Property Plant And Equipment Net	56K	38K	98K	59K	67.9K	55.2K
Net Debt	(79.4M)	(146.3M)	(16.5M)	(19.1M)	(22.0M)	(23.1M)
Retained Earnings	(23.1M)	(55.2M)	(150.3M)	(196.0M)	(176.4M)	(167.6M)
Accounts Payable	5.7M	5.6M	6.4M	507K	583.1K	553.9K
Cash	79.4M	146.3M	45.9M	49.3M	56.6M	71.0M
Non Current Assets Total	121K	70K	1.2M	1.1M	1.3M	1.4M
Cash And Short Term Investments	79.4M	146.3M	90.3M	83.1M	95.6M	88.2M
Liabilities And Stockholders Equity	80.9M	149.5M	94.2M	89.1M	102.5M	91.4M
Non Current Liabilities Total	97.2M	8K	29.4M	30.1M	27.1M	26.2M
Other Current Assets	1.4M	6.3M	2.7M	4.9M	5.6M	3.4M
Other Stockholder Equity	(97.1M)	46.4M	199.5M	250.8M	288.4M	302.8M
Total Liab	104.0M	8.8M	45.1M	34.3M	30.9M	32.0M
Net Invested Capital	(23.1M)	140.7M	78.5M	84.9M	97.7M	60.5M
Total Current Assets	80.8M	149.4M	93.0M	88.0M	101.2M	90.9M
Accumulated Other Comprehensive Income	(15K)	(149.5M)	(161K)	9K	8.1K	8.5K
Net Working Capital	74.0M	140.6M	77.3M	83.8M	96.4M	83.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC